Figure 4
From: Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
Survival analysis by mutation status. Overall survival (a) and event-free survival (b) of de novo acute myeloid leukemia patients younger than 60 years of age with concomitant mutations in DNMT3A, FLT3, and NPM1 (AMLDNMT3A/FLT3/NPM1) in comparison to those within other mutation subgroups in this study. Overall survival (c) and event-free survival (d) of patients with AML harboring NPM1 mutation in conjunction with wild-type DNMT3A (NPM1 group) or mutant DNMT3A (NPM1/DNMT3A group). Overall survival (e) of patients with CN-AML harboring NPM1 mutations with concomitant FLT3 (NPM1/FLT3 group) or DNMT3A (NPM1/DNMT3A group).